Vaccines--Duration of Immunity Challenge Study

This abstract from PubMed


Vet Ther. 2004 Fall;5(3):173-86.

Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges.

Abdelmagid OY, Larson L, Payne L, Tubbs A, Wasmoen T, Schultz R.

Schering-Plough Animal Health, Research and Development, 21401 West Center Road, Elkhorn, NE, USA.

The results obtained from this study confirmed that dogs vaccinated subcutaneously with a commercially available multivalent vaccine containing modified-live Canine Distemper Virus (CDV), Canine Adenovirus Type 2 (CAV-2), Canine Parvovirus Type 2b (CPV-2b) and Canine Parainfluenza Virus (CPI) antigens were protected against sequential experimental challenge by virulent canine parvovirus type 2b, infectious canine hepatitis virus, and canine distemper virus administered 55-57 month after initial vaccination given at 7-8 weeks of age. All 10 vaccinates (100%) were protected against clinical diseases and mortality following parvovirus and infectious canine hepatitis experimental infections. All vaccinates (100%) were protected against mortality and (90%) were protected against clinical disease following distemper challenge. Therefore, the data obtained from this study supports at least 4 year duration of immunity for these three "core" fractions in the combination vaccine.